Our analysis summarizes baseline subject demographics , distribution of baseline pathogens isolated from blood cultures , clinical response rates at Day 4 , and clinical cure rates at end of therapy and test of cure ( 8 to 15 days after end of therapy ) in subjects with bacteremic CABP in the ceFtarOline Community-acquired pneUmonia trial vS ceftriaxone in hospitalized patients ( FOCUS ) studies .